What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
CIK: 0001582384
Total reported value
$228.5M
$228.5M
6 檔
73.6%
At the close of Q2 2025, Wildcat Capital Management, LLC disclosed equity holdings valued at approximately $228.5M, spread across 6 reported holdings.
In Q2 2025, Wildcat Capital Management, LLC adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ULCC | Frontier Group Holdings Inc | Stock-Other | 60.52% | +3.84% | — | |
| 2 | RLX | Rlx Technology Inc-adr | Stock-Other | 23.70% | — | — | |
| 3 | TIC | Tic Solutions Inc | Stock-Other | 9.84% | — | — | |
| 4 | URGN | UroGen Pharma Ltd. | Stock-Other | 4.03% | — | — | |
| 5 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.85% | -4.05% | — | |
| 6 | ✓ | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RLX | Rlx Technology Inc-adr | +5.6% | — | Unchanged |
| 2 | URGN | UroGen Pharma Ltd. | +1.1% | — | Unchanged |
| 3 | TIC | Tic Solutions Inc | +0.9% | — | Unchanged |
| 4 | ✓ | 0% | — | Unchanged | |
| 5 | ALLO | Allogene Therapeutics Inc | -0.4% | — | Unchanged |
| 6 | KRON1USD | Kronos Bio Inc | -0.6% | EXIT | Sold out |
| 7 | 260 | Centessa Pharmaceuticals-adr | -2.2% | EXIT | Sold out |
| 8 | ULCC | Frontier Group Holdings Inc | -4.5% | — | Unchanged |
According to official SEC Form 13F filings, Wildcat Capital Management, LLC reported a total U.S. public equity portfolio value of $228.5M across 6 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ULCC, RLX, TIC) accounted for 73.6% of total reported equity market value during Q2 2025.
Top Position Liquidated / Trimmed
260
前期市值: $4.1M
During Q2 2025, Wildcat Capital Management, LLC's top holdings by market value included ULCC (60.5%)、RLX (23.7%)、TIC (9.8%). The largest single position, ULCC, represented 60.5% of total portfolio value.
In Q2 2025, Wildcat Capital Management, LLC made 2 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.